AstraZeneca Stock Rating Reaffirmed by Societe Generale (AZN)
AstraZeneca (LON: AZN)‘s stock had its “sell” rating restated by equities researchers at Societe Generale in a report issued on Monday. They currently have a $42.39 (2675 GBX) target price on the stock.
Shares of AstraZeneca opened at 3068.375 on Monday. AstraZeneca has a 52 week low of GBX 2578.50 and a 52 week high of GBX 3099.00. The stock’s 50-day moving average is currently GBX 0.. The company’s market cap is £38.201 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Wednesday, January 9th. They now have a $45.91 price target on the stock. Separately, analysts at Nordea Equity Research reiterated a “sell” rating on shares of AstraZeneca in a research note to investors on Friday, January 4th. They now have a $43.37 price target on the stock.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.